Search Results Search Sort by RelevanceMost Recent Case and Commentary May 2022 How Does Cognitive Bias Affect Conversations With Patients About Dietary Supplements? Ila M. Harris, PharmD, Christine C. Danner, PhD, and David J. Satin, MD Some allopathic clinicians’ biases influence the information they draw upon to make decisions and offer recommendations. AMA J Ethics. 2022;24(5):E368-375. doi: 10.1001/amajethics.2022.368. Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410. Case and Commentary Sep 2023 What Makes Palliative Mental Health Care Ethical Health Care? Virginia A. Brown, PhD, MA and Ashley Trust, MD Treatment-resistant schizophrenia can create a high disease burden for some patients, making it hard to get good outcomes. AMA J Ethics. 2023;25(9):E674-677. doi: 10.1001/amajethics.2023.674. In the Literature Jul 2024 How Should Harm Reduction Strategies Differ for Adolescents and Adults? Brady J. Heward, MD, Amy M. Yule, MD, and Peter R. Jackson, MD Recent increases in adolescent mortality from overdose have outpaced increases in mortality in members of the general population. AMA J Ethics. 2024;26(7):E534-545. doi: 10.1001/amajethics.2024.534. Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512.
Case and Commentary May 2022 How Does Cognitive Bias Affect Conversations With Patients About Dietary Supplements? Ila M. Harris, PharmD, Christine C. Danner, PhD, and David J. Satin, MD Some allopathic clinicians’ biases influence the information they draw upon to make decisions and offer recommendations. AMA J Ethics. 2022;24(5):E368-375. doi: 10.1001/amajethics.2022.368.
Policy Forum May 2022 Which Features of Dietary Supplement Industry, Product Trends, and Regulation Deserve Physicians’ Attention? Amy B. Cadwallader, PhD and AMA Council on Science and Public Health Illegal, fraudulent, adulterated, or improperly labeled products should be regarded as sources of possible clinical and ethical harm to patients. AMA J Ethics. 2022;24(5):E410-418. doi: 10.1001/amajethics.2022.410.
Case and Commentary Sep 2023 What Makes Palliative Mental Health Care Ethical Health Care? Virginia A. Brown, PhD, MA and Ashley Trust, MD Treatment-resistant schizophrenia can create a high disease burden for some patients, making it hard to get good outcomes. AMA J Ethics. 2023;25(9):E674-677. doi: 10.1001/amajethics.2023.674.
In the Literature Jul 2024 How Should Harm Reduction Strategies Differ for Adolescents and Adults? Brady J. Heward, MD, Amy M. Yule, MD, and Peter R. Jackson, MD Recent increases in adolescent mortality from overdose have outpaced increases in mortality in members of the general population. AMA J Ethics. 2024;26(7):E534-545. doi: 10.1001/amajethics.2024.534.
Case and Commentary Jul 2024 How Should Risks and Benefits of Short-Acting Opioids Be Evaluated in the Care of Inpatients With OUD? Kathryn A. Dong, MD, MSc and Katherine M. Duthie, PhD, HEC-C Severe withdrawal, risk of patient-initiated discharge, and some inpatients’ uses of substances prompt questions considered in this commentary. AMA J Ethics. 2024;26(7):E512-519. doi: 10.1001/amajethics.2024.512.